Assessment of TVT and STS Risk Score Performances in Patients Undergoing Transcatheter Aortic Valve Replacement

The Society of Thoracic Surgeons (STS) score has been used to risk stratify patients undergoing transcatheter aortic valve replacement (TAVR). The Transcatheter Valve Therapy (TVT) score was developed to predict in-hospital mortality in high/prohibitive-risk patients. Its performance in low and inte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Society for Cardiovascular Angiography & Interventions 2023-05, Vol.2 (3), p.100600, Article 100600
Hauptverfasser: Al-Azizi, Karim, Shih, Emily, DiMaio, J. Michael, Squiers, John J., Moubarak, Ghadi, Kluis, Austin, Banwait, Jasjit K., Ryan, William H., Szerlip, Molly I., Potluri, Srinivasa P., Hamandi, Mohanad, Lanfear, Allison T., Meidan, Talia G., Stoler, Robert C., Mixon, Timothy A., Krueger, Anita R., Mack, Michael J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The Society of Thoracic Surgeons (STS) score has been used to risk stratify patients undergoing transcatheter aortic valve replacement (TAVR). The Transcatheter Valve Therapy (TVT) score was developed to predict in-hospital mortality in high/prohibitive-risk patients. Its performance in low and intermediate-risk patients is unknown. We sought to compare TVT and STS scores’ ability to predict clinical outcomes in all-surgical-risk patients undergoing TAVR. Consecutive patients undergoing TAVR from 2012-2020 within a large health care system were retrospectively reviewed and stratified by STS risk score. Predictive abilities of TVT and STS scores were compared using observed-to-expected mortality ratios (O:E) and area under the receiver operating characteristics curves (AUCs) for 30-day and 1-year mortality. We assessed a total of 3270 patients (mean age 79 ± 9 years, 45% female), including 191 (5.8%) low-risk, 1093 (33.4%) intermediate-risk, 1584 (48.4%) high-risk, and 402 (5.8%) inoperable. Mean TVT and STS scores were 3.5% ± 2.0% and 6.1% ± 4.3%, respectively. Observed 30-day and 1-year mortality were 2.8% (92/3270; O:E TVT 0.8 ± 0.16 vs STS 0.46 ± 0.09), and 13.2% (432/3270), respectively. In the all-comers population, both TVT and STS risk scores showed poor prediction of 30-day (AUC: TVT 0.68 [0.62-0.74] vs STS 0.64 [0.58-0.70]), and 1-year (AUC: TVT 0.65 [0.62-0.58] vs STS 0.65 [0.62-0.58]) mortality. After stratifying by surgical risk, discrimination of the TVT and STS scores remained poor in all categories at 30 days and 1 year. An updated TAVR risk score with improved predictive ability across all-surgical-risk categories should be developed based on a larger national registry. [Display omitted] •The 30-day predictive ability of the transcatheter valve therapy and Society of Thoracic Surgeons scores was poor in all categories.•The 1-year predictive ability of the transcatheter valve therapy and Society of Thoracic Surgeons scores was poor in all categories.•An updated transcatheter aortic valve replacement risk score should be developed with improved predictive.
ISSN:2772-9303
2772-9303
DOI:10.1016/j.jscai.2023.100600